SB477 Relative to increasing transparency in the 340B Drug Pricing Program.
Relative to increasing transparency in the 340B Drug Pricing Program.
Impact Score — How Does This Bill Affect You?
Overall Impact Score
Mixed
Scale: 1 (harmful) to 10 (beneficial)
Your Wallet
Greater transparency could help ensure 340B savings are passed on to patients, potentially lowering out-of-pocket drug costs for NH residents using safety-net providers.
Your Community
Transparency in drug pricing programs helps ensure hospitals and clinics actually use discounted drug savings to serve low-income and uninsured patients as intended.
Your Freedom
Enhances public access to information about how taxpayer-subsidized drug discounts are being used, supporting government accountability.
Status
Refer to Interim Study, Motion Adopted, Voice Vote; 03/05/2026; Senate Journal 5
Sponsor
Tim McGough (R)
The Short Version
Increases transparency requirements for the 340B Drug Pricing Program, which provides discounted drugs to safety-net providers. Would require covered entities to report how savings from the program are used to benefit patients.
Who's Behind This Bill?
Who Benefits
- ▲ Patients at safety-net hospitals and clinics
- ▲ Uninsured and underinsured NH residents
- ▲ Taxpayers seeking accountability
Who Pays the Price
- ▼ Hospitals and clinics participating in 340B that face new reporting burdens
- ▼ Entities that may not be passing savings to patients
Bill statuses as of May 2026. Check LegiScan or NH General Court for the latest.
This bill was auto-scored using AI analysis of the bill text and legislative data. Scores may be refined as we review more bills.